FDA Approves Lazertinib-Amivantamab Combo for Lung Cancer
HEALTH DESK The FDA has approved the combination of lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR…




